EN
Turkish Validity and Reliability Study of the Digital Vaccine Literacy Scale
Abstract
Objectives: This study aimed to assess the validity and reliability of the Turkish version of the Digital Vaccine Literacy (DVL) scale.
Methods: This methodological study was conducted with 236 staff working at a foundation university hospital between September 2023 and April 2024. Data were collected using the Personal Information Form and DVL scale. The linguistic validity, content validity, exploratory factor analysis, and confirmatory factor analysis of the scale were conducted. Reliability was evaluated through item-total correlations, Cronbach's alpha coefficient, and test-retest reliability. Data were analyzed in SPSS 27.0 and AMOS 22.0 package programs.
Results: The study revealed 3 dimensions comprising 7 items, with factor loadings ranging from 0.612 to 0.851, explaining 78.63% of the total variance. The fit measures were acceptable (χ2/df = 3.271; RMSEA = 0.072; CFI = 0.912; NFI = 0.875; GFI = 0.874; TLI = 0.889; IFI = 0.876; p < 0.001) in confirmatory factor analysis. The overall Cronbach's alpha value of the scale was 0.730, while the sub-dimensions were 0.791, 0.891 and 0.781, respectively. The test-retest reliability correlation was positive, very strong and statistically significant (r=0.962, p<0.001).
Conclusions: It was found that the factor structure of the Turkish version of the DVL is the same as the factor structure of the original version, and it is a valid and reliable tool. Measurement of digital vaccine literacy will play a significant role in developing education strategies, accessing accurate information, preserving public health, supporting vaccine decision-making, and enhancing digital health skills.
Keywords
Ethical Statement
Approval was secured via email from the creators of the scale to conduct a validity and reliability study in Turkish. Following this, ethical clearance was obtained from the XXX University Ethics Committee (dated March 22, 2023, reference number 101249), and permission to conduct the study was granted by the hospital where the research was conducted (dated March 1, 2023, reference number 98706). Participants were informed about the study, and both written and verbal consent were obtained.
References
- 1. Fan J, Toth I, Stephenson RJ. Recent Scientific Advancements towards a Vaccine against Group A Streptococcus. Vaccines (Basel). 2024;12(3):272. https://doi.org/10.3390/vaccines12030272.
- 2. Zasada AA, Darlińska A, Wiatrzyk A, et al. COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic. Viruses. 2023;15(9):1786. https://doi.org/10.3390/v15091786.
- 3. Goel RK, Nelson MA. COVID-19 internet vaccination information and vaccine administration: evidence from the United States. Journal of Economics and Finance. 2021;45(4):716-734. https://doi.org/10.1007/s12197-021-09551-x.
- 4. Loomba S, De Figueiredo A, Piatek SJ, De Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nature Human Behaviour. 2021;5(3):337-348. https://doi.org/10.1038/s41562-021-01056-1.
- 5. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015;33(34):4161-4164. https://doi.org/10.1016/j.vaccine.2015.04.036.
- 6. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nature Medicine. 2021;27(8):1338-1339. https://doi.org/10.1038/s41591-021-01459-7.
- 7. Fitzpatrick M. The Cutter Incident: How America's First Polio Vaccine Led to a Growing Vaccine Crisis. J R Soc Med. 2006;99(3):156.
- 8. Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine. 2017;35(47):6355-6358. https://doi.org/10.1016/j.vaccine.2017.09.089.
Details
Primary Language
English
Subjects
Public Health (Other)
Journal Section
Research Article
Early Pub Date
December 10, 2024
Publication Date
January 1, 2025
Submission Date
June 16, 2024
Acceptance Date
September 16, 2024
Published in Issue
Year 2025 Volume: 16 Number: 1